Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.

NEXT STORY
Medicenna to Commence Trading on Nasdaq
PREV STORY
Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptevo Therapeutics Reports First Quarter 2018 Financial Results

Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward ...

author_avatar
NASDAQ Market News

Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update

-   Expanding Controlled IL-12 platform to explore additional tumor types -   Cash runway extended ...

author_avatar
NASDAQ Market News

Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema

ALPHARETTA, Ga., April 20, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a late-stage ...

author_avatar
NASDAQ Market News